UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/537,850	04/18/2007	Jianhe Chen	120143.453USPC	8520
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE			EXAMINER	
			BELYAVSKYI, MICHAIL A	
SUITE 5400 SEATTLE, WA 98104		ART UNIT	PAPER NUMBER	
·			1644	
			MAIL DATE	DELIVERY MODE
			12/04/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/537,850	CHEN, JIANHE				
Office Action Summary	Examiner	Art Unit				
	Michail A. Belyavskyi	1644				
The MAILING DATE of this communication app	pears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA.  - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period v. Failure to reply within the set or extended period for reply will, by statute. Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>18 A</u>	oril 2007					
	action is non-final.					
·—						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-41</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-41</u> are subject to restriction and/or €	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)☐ All b)☐ Some * c)☐ None of:						
a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
	·					
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da 5) Notice of Informal P					
Information Disclosure Statement(s) (PTO/SB/08)     Paper No(s)/Mail Date	6) Other:	atom / ppiloution				

Application/Control Number: 10/537,850 Page 2

Art Unit: 1644

## **DETAILED ACTION**

1. Applicant's amendment, filed 04/18/07 is acknowledged.

Claims 1-41 are pending.

## Restriction

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted:

- I. Claims 1- 20 are drawn to a method for the in vitro antigen specific activation of antibody producing cells, wherein said antigen is a peptide comprising at least one epitope, recited in claims 18-20.
- II. Claims 1-17 and 21-23 are drawn to a method for the in vitro antigen specific activation of antibody producing cells, wherein said antigen is a peptide comprising at least one epitope, recited in claims 21-23.
- III. Claims 1-17, 24-26 are drawn to a method for the in vitro antigen specific activation of antibody producing cells, wherein said antigen is a peptide comprising at least one epitope, recited in claims 24-26.
- IV. Claims 1-17, 27-30 are drawn to a method for the in vitro antigen specific activation of antibody producing cells, wherein said antigen is a peptide comprising at least one epitope, recited in claims 27-30.
- V. Claims 1-17, 31-33 are drawn to a method for the in vitro antigen specific activation of antibody producing cells, wherein said antigen is a peptide comprising at least one epitope, recited in claims 31-33
- VI. Claims 34-37 is drawn to an antibody producing cell
- VII. Claims 38-39 are drawn to an antibody and a pharmaceutical composition comprising said antibody.
- VIII. Claim 41 is drawn to a method of therapeutically and/or prophylactically treating a subject, comprising administering to the subject an antibody.

Application/Control Number: 10/537,850 Page 3

Art Unit: 1644

IX. Claim 42 is drawn to a method of detecting an antigen

3. The inventions listed as Groups I-IX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

As was also found in the International Search Report, the Invention of Group I was found to have no special technical feature that defined the contribution over the prior art of Shiba et al (IDS).

Shiba et al., teaches a method for the in vitro antigen specific activation of antibody producing cells.

- 4. Since Applicant's Inventions do not contribute a special technical feature when viewed over the prior art they do not have a single general inventive concept and so lack unity of invention.
- 5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840 The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/537,850 Page 4

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Michail A Belyavskyi/ Primary Examiner, Art Unit 1644